CEDRA Corporation Announces New Company Name
CEDRA Corporation
, a division of
Worldwide Clinical Trials
,announces its new company name, Worldwide Clinical Trials Drug Development Solutions. This unified name adds to the continuity and full-service offerings our companies collectively provide.
Worldwide Clinical Trials Drug Development Solutions continues to offer Bioanalytical Sciences and Clinical Research Services, as well as specialized studies to determine the effects of dose, formulation, dosing regimen, drug interactions, genotype, gender and other factors on pharmacokinetics.
Worldwide Clinical Trials and Worldwide Clinical Trials Drug Development Solutions will use their combined medical and scientific expertise to provide service in drug development. Worldwide Clinical Trials specializes in mid-/late-phase, and Worldwide Clinical Trials Drug Development Solutions specializes in bioanalytical/early-phase clinical trials, covering all phases in the clinical trials process.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.
